Pulse IVL
Phase 3- Indications
- Peripheral arterial disease, Coronary artery disease, Carotid artery disease
Company intelligence / Profile preview
Amplitude Vascular Systems' Pulse IVL™ system has demonstrated efficacy in preclinical and early human studies by safely fracturing vascular calcium to restore blood flow. The pivotal POWER PAD II U.S. IDE trial is ongoing for femoropopliteal arteries, aiming to enroll up to 120 patients at 20 sites. Early results show reduced leg pain and improved walking ability. Additional IDE trials are planned or underway for coronary and carotid indications. The device remains investigational as of mid/late 2025.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Amplitude Vascular Systems.